
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson’s disease with motor fluctuations. NeuroDerm, a subsidiary of Mitsubishi Tanabe Pharma, announced the positive results in January 2023 of this 24h/d subcutaneous infusion of levodopa/carbidopa, with a marked improvement in ON time without bothersome dyskinesias and a reduction in…

The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured by Acorda and distributed by Esteve. Our Clinical Trial Unit evaluated it during 2015 and 2016. It is a new therapy for motor blocks that require an immediate response. Its use at the request of the patient’s needs is noteworthy.



Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations. – We are leading the inclusion internationally of a trial with sublingual Apomorphine. Our Unit leads the inclusion of randomized patients comparing sublingual apomorphine versus the classic subcutaneous apomorphine for the indication in blocking off.




We have reached the first position, in December 2019, in the international inclusion of patients in the trial with sublingual apomorphine and motor blocks in Parkinson. We are also leading the national inclusion of patients in the Clarity AD trial (monoclonal anti-amyloid antibody in early Alzheimer) Finally, in the Graduate trial (monoclonal subcutaneous in Alzheimer)…

The UDIC has been selected to initiate a line of several clinical trials with this D1 dopamine agonist, with a similar mechanism of action to Apomorphine. It will be evaluated in initial Parkinson’s and also in advanced Parkinson’s disease, as add on levodopa therapy. An open label extension is planned.